GAIA
NK-like cell
platform
A breakthrough in
eliminating solid tumors
A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.
GAIA's antibody-anchoring
and activating peptide
A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors
GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.
Core Technology IINews
-
News
The clinical trial “GAIA-102 Intraperitoneal Administration in Patients with Advanced Gastrointestinal Cancer of Microsatellite Stable with Malignant Ascites” has been adopted by AMED as part of ’Research Project for Practical Applications of Regenerative Medicine’.
More -
News
At the 96th Annual Meeting of Japanese Gastric Cancer Association, an interim report on the Phase Ⅰ/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer will be presented.
More -
News
At the 9th Annual Innate Killer Summit (IKS2024), Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors will be presented.
More -
News
At the 38th Annual Meeting of Society of Immunotherapy of Cancer (SITC2023), Interim Report of Phase I Clinical Trial of Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102
More -
News
At the 38th Society for Immunotherapy of Cancer (SITC 2023), an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.
More